全文获取类型
收费全文 | 161211篇 |
免费 | 16555篇 |
国内免费 | 6858篇 |
专业分类
耳鼻咽喉 | 2683篇 |
儿科学 | 1965篇 |
妇产科学 | 2147篇 |
基础医学 | 16300篇 |
口腔科学 | 3784篇 |
临床医学 | 13250篇 |
内科学 | 22088篇 |
皮肤病学 | 2611篇 |
神经病学 | 891篇 |
特种医学 | 6870篇 |
外国民族医学 | 227篇 |
外科学 | 19168篇 |
综合类 | 29352篇 |
现状与发展 | 33篇 |
预防医学 | 5240篇 |
眼科学 | 1174篇 |
药学 | 10499篇 |
71篇 | |
中国医学 | 5114篇 |
肿瘤学 | 41157篇 |
出版年
2024年 | 464篇 |
2023年 | 2656篇 |
2022年 | 5275篇 |
2021年 | 7006篇 |
2020年 | 6181篇 |
2019年 | 5350篇 |
2018年 | 5155篇 |
2017年 | 5979篇 |
2016年 | 6618篇 |
2015年 | 7330篇 |
2014年 | 10707篇 |
2013年 | 9922篇 |
2012年 | 9681篇 |
2011年 | 10485篇 |
2010年 | 8334篇 |
2009年 | 8014篇 |
2008年 | 8205篇 |
2007年 | 8711篇 |
2006年 | 7909篇 |
2005年 | 7062篇 |
2004年 | 5700篇 |
2003年 | 4932篇 |
2002年 | 4135篇 |
2001年 | 3884篇 |
2000年 | 3255篇 |
1999年 | 2651篇 |
1998年 | 2352篇 |
1997年 | 2215篇 |
1996年 | 1912篇 |
1995年 | 1657篇 |
1994年 | 1576篇 |
1993年 | 1108篇 |
1992年 | 1050篇 |
1991年 | 920篇 |
1990年 | 774篇 |
1989年 | 692篇 |
1988年 | 626篇 |
1987年 | 539篇 |
1986年 | 430篇 |
1985年 | 467篇 |
1984年 | 453篇 |
1983年 | 306篇 |
1982年 | 334篇 |
1981年 | 271篇 |
1980年 | 290篇 |
1979年 | 203篇 |
1978年 | 148篇 |
1977年 | 115篇 |
1976年 | 97篇 |
1975年 | 61篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
《Diagnostic and interventional imaging》2020,101(9):555-564
PurposeThe purpose of this study was to determine whether computed tomography (CT)-based machine learning of radiomics features could help distinguish autoimmune pancreatitis (AIP) from pancreatic ductal adenocarcinoma (PDAC).Materials and MethodsEighty-nine patients with AIP (65 men, 24 women; mean age, 59.7 ± 13.9 [SD] years; range: 21–83 years) and 93 patients with PDAC (68 men, 25 women; mean age, 60.1 ± 12.3 [SD] years; range: 36–86 years) were retrospectively included. All patients had dedicated dual-phase pancreatic protocol CT between 2004 and 2018. Thin-slice images (0.75/0.5 mm thickness/increment) were compared with thick-slices images (3 or 5 mm thickness/increment). Pancreatic regions involved by PDAC or AIP (areas of enlargement, altered enhancement, effacement of pancreatic duct) as well as uninvolved parenchyma were segmented as three-dimensional volumes. Four hundred and thirty-one radiomics features were extracted and a random forest was used to distinguish AIP from PDAC. CT data of 60 AIP and 60 PDAC patients were used for training and those of 29 AIP and 33 PDAC independent patients were used for testing.ResultsThe pancreas was diffusely involved in 37 (37/89; 41.6%) patients with AIP and not diffusely in 52 (52/89; 58.4%) patients. Using machine learning, 95.2% (59/62; 95% confidence interval [CI]: 89.8–100%), 83.9% (52:67; 95% CI: 74.7–93.0%) and 77.4% (48/62; 95% CI: 67.0–87.8%) of the 62 test patients were correctly classified as either having PDAC or AIP with thin-slice venous phase, thin-slice arterial phase, and thick-slice venous phase CT, respectively. Three of the 29 patients with AIP (3/29; 10.3%) were incorrectly classified as having PDAC but all 33 patients with PDAC (33/33; 100%) were correctly classified with thin-slice venous phase with 89.7% sensitivity (26/29; 95% CI: 78.6–100%) and 100% specificity (33/33; 95% CI: 93–100%) for the diagnosis of AIP, 95.2% accuracy (59/62; 95% CI: 89.8–100%) and area under the curve of 0.975 (95% CI: 0.936–1.0).ConclusionsRadiomic features help differentiate AIP from PDAC with an overall accuracy of 95.2%. 相似文献
32.
33.
34.
35.
36.
37.
38.
Family-centered care (FCC) for sick newborns is emerging as a paradigmatic shift in the practice of facility-based newborn care. It seeks to transforming a provider-centered model into a client-centered one and thus build a new therapeutic alliance. FCC is the cornerstone of continuum of care, imparting caregiving competencies to parents/caregivers both within institutions as well as after the discharge. This has potential gains for the newborn, family members, and facility-level staff. The initial model piloted in tertiary-care settings is now undergoing translation at five sites across the country; the outcomes are keenly awaited. 相似文献
39.
目的探索阿帕替尼治疗晚期及术后复发肺肉瘤样癌的疗效。方法收集2016年6月至2019年8月Ⅲ~Ⅳ期及术后复发的肺肉瘤样癌患者21例,口服阿帕替尼(250~425 mg/d)治疗,30 d为1个疗程,观察并分析疗效及评价安全性。结果21例患者中,完全缓解(CR)为0,部分缓解(PR)为14.3%(3例),稳定(SD)为33.3%(7例),疾病进展(PD)为52.4%(11例);客观反应率(ORR)为13.3%(3例),疾病控制率(DCR)为47.6%(10例)。中位总生存期(mOS)为4.6个月,中位无进展生存期(mPFS)为1.0个月。病灶≥6 cm(或≥5 cm)较<6 cm(或<5 cm)平均OS明显缩短,差异有统计学意义(P<0.05);术后分期Ⅰ~Ⅱ期较Ⅲ~Ⅳ期平均OS明显延长(P<0.05)。位于中央的病灶较周围的病灶平均OS明显缩短,差异有统计学意义(P<0.01)。性别、年龄(>60岁,≤60岁)、吸烟史(是/否)对疗效影响差异无统计学意义。常见不良反应包括高血压38.1%(8例)、蛋白尿23.8%(5例)、手足综合征28.6%(6例)、腹泻28.6(6例)、骨髓抑制38.1%(8例)。结论阿帕替尼治疗晚期及术后复发肺肉瘤样癌具有一定疗效,不良反应可控,病灶大小、位置及分期可能是疗效的独立影响因素。 相似文献
40.